Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 209,921,004 papers from all fields of science
Search
Sign In
Create Free Account
ISIS 2503
Known as:
ISIS-2503
, ISIS2503
A synthetic oligodeoxynucleotide. Functioning as an anti-sense agent, it hybridizes to the translation initiation region of the human mRNA for the…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Phosphorothioate Oligonucleotides
gemcitabine/ISIS 2503
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Aloperine inhibits proliferation, migration and invasion and induces apoptosis by blocking the Ras signaling pathway in human breast cancer cells
Delong Tian
,
Yanhai Li
,
Xinxin Li
,
Zhenzhen Tian
Molecular Medicine Reports
2018
Corpus ID: 52056595
Aloperine (Alo), as a quinolizidine alkaloid extracted from S. alopecuroide, has the positive activities of anti-inflammatory…
Expand
Highly Cited
2004
Highly Cited
2004
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
S. Alberts
,
M. Schroeder
,
+7 authors
T. Fitch
Journal of Clinical Oncology
2004
Corpus ID: 24747552
PURPOSE Gemcitabine remains the standard therapy for metastatic pancreatic adenocarcinoma (ACA), but has limited activity. ISIS…
Expand
2004
2004
Pharmacokinetics and Tissue Disposition in Monkeys of an Antisense Oligonucleotide Inhibitor of Ha-Ras Encapsulated in Stealth Liposomes
R. Yu
,
R. Geary
,
+15 authors
A. Levin
Pharmaceutical Research
2004
Corpus ID: 20425031
AbstractPurpose. This study examined the pharmacokinetics and tissue distribution of an antisense oligonucleotide ISIS 2503…
Expand
Highly Cited
2003
Highly Cited
2003
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
A. Adjei
,
G. Dy
,
+11 authors
F. A. Dorr
Clinical Cancer Research
2003
Corpus ID: 12819221
PURPOSE The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS…
Expand
2003
2003
Gateways to clinical trials.
M. Bayes
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2003
Corpus ID: 35376805
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
Highly Cited
2001
Highly Cited
2001
A Phase I trial of h‐ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
C. C. Cunningham
,
J. Holmlund
,
+5 authors
J. Nemunaitis
Cancer
2001
Corpus ID: 33560711
Abnormal expression of Ras proteins frequently is found with oncogenic transformation making ras a promising therapeutic target…
Expand
2001
2001
Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
M. Morse
Current opinion in molecular therapeutics (Print)
2001
Corpus ID: 7918845
ISIS-2503, a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression, is being developed by Isis Pharmaceuticals Inc as…
Expand
Highly Cited
2001
Highly Cited
2001
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
R. Yu
,
R. Geary
,
+7 authors
A. Levin
Journal of Pharmacy and Science
2001
Corpus ID: 34763539
The plasma pharmacokinetics and tissue disposition of ISIS 2503 were studied in mice following single and multiple bolus…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE